A Phase 3 interventional study of RSVPreF3 OA investigational vaccine and Placebo (Saline solution) in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 40 sites in 7 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 3rd largest by enrollment, is one of 7 that started in 2024, is one of 15 in phase 3, and was the 13th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 7 started in 2024.
This study's enrollment of 2,620 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 976 across the 17 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline: 1 open now, 5 under way, 3 of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 6th largest by enrollment, is one of 6 that started in 2024, is one of 21 in phase 3, and was the 35th registered.
GlaxoSmithKline’s Respiratory Syncytial Virus Infections studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, from their registry updates:
Among GlaxoSmithKline’s 40 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the current study is to evaluate the immune response of the RSVPreF3 OA investigational vaccine in older adults (OA) at least (>=) 60 years of age (YOA) in China compared to OA in the same age range to be enrolled from overseas countries that participated in the RSV OA=ADJ-006 (NCT04886596) study, since the vaccine efficacy against lower respiratory tract disease (LRTD) has been demonstrated following a single dose of the RSVPreF3 OA investigational vaccine in the global efficacy study RSV OA=ADJ-006. In addition, the safety (in all participants) , reactogenicity and occurrence of RSV-associated acute respiratory illness (ARI) (in study participants in China only) after administration of the vaccine are also assessed in the current study. No ARI surveillance will be conducted for the overseas participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical Conditions:
Prior/Concomitant Therapy:
Prior/Concurrent Clinical Study Experience:
Other Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overseas older adults (OA) participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6).
Biological: RSVPreF3 OA investigational vaccine
Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later).
Biological: RSVPreF3 OA investigational vaccine
Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later).
Drug: Placebo (Saline solution)
One dose of the RSVPreF3 OA investigational vaccine is administered intramuscularly at Day 1.
One dose of placebo is administered intramuscularly at Day 1.
RSV-A Neutralizing Titers Expressed as Adjusted Geometric Mean Titers (GMTs) at 1 Month Post RSVPreF3 OA Vaccination
RSV-A neutralizing titers were determined by neutralization assay and the results were expressed as GMTs. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.
Time frame: At Day 31
Percentage of Participants With Seroresponse for RSV-A Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination
Seroresponse was defined as at least a 4 fold (≥4) increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration).
Time frame: At Day 31 compared to baseline (Day 1)
RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA Vaccination
RSV-B neutralizing titers were determined by neutralization assay and the results were expressed as GMTs. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.
Time frame: At Day 31
Percentage of Participants With Seroresponse for RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination
Time frame: At Day 31 compared to baseline (Day 1)
RSV-A Neutralizing Titers Expressed as Unadjusted GMTs at Baseline, 1 Month and 6 Months Post RSVPreF3 OA Vaccination
Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. Unadjusted GMT is a descriptive statistic calculated directly from the observed titer values at pre-vaccination and at 1-month post-vaccination timepoints for all participants in the analysis set, without any statistical modelling or adjustment for covariates.
Time frame: At Day 1 (baseline), Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination)
RSV-B Neutralizing Titers Expressed as Unadjusted GMTs at Baseline, 1 Month and 6 Months Post RSVPreF3 OA Vaccination
Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. Unadjusted GMT is a descriptive statistic calculated directly from the observed titer values at pre-vaccination and at 1-month post-vaccination timepoints for all participants in the analysis set, without any statistical modelling or adjustment for covariates.
Time frame: At Day 1 (baseline), Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination)
Percentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 1 Month and 6 Months Post RSVPreF3 OA Vaccination
Time frame: At Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination) compared to baseline (Day 1)
RSV-A and RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA Vaccination Between RSV OA Overseas (RSV OA=ADJ-006 Study) vs RSV OA Vaccine Group (China) Group
This outcome measure compares the adjusted GMTs for RSV-A and RSV-B for the RSV OA vaccine Group (China) to the selected immunogenicity subset of the global efficacy study RSV OA=ADJ-006 \[RSV OA Overseas (RSV OA=ADJ-006 study) group\]. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.
Time frame: At Day 31
Percentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination Between RSV OA Overseas (RSV OA=ADJ-006 Study) vs RSV OA Vaccine Group (China) Group
This outcome measure compares the seroresponse for RSV-A and RSV-B neutralizing titers in the RSV OA vaccine Group (China) group to the selected immunogenicity subset of the global efficacy study RSV OA=ADJ-006 \[RSV OA Overseas (RSV OA=ADJ-006 study) group\].
Time frame: At Day 31 compared to baseline (Day 1)
Number of Participants With Any and Real Time Polymerase Chain Reaction (RT-PCR) Confirmed RSV-A/B Associated Acute Respiratory Illness (ARI) and Lower Respiratory Tract Disease (LRTD) Cases
ARI and LRTD were reported based on the case definition. Case definition for ARI: presence of at least 2 respiratory symptoms/signs for at least 24 hours or at least 1 respiratory symptom/sign and 1 systemic symptom/sign for at least 24 hours. Case definition for LRTD: presence of at least 2 lower respiratory symptoms/signs for at least 24 hours including at least 1 lower respiratory sign or at least 3 lower respiratory symptoms for at least 24 hours.
Time frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
Duration of Episodes for RSV-confirmed ARI and LRTD Cases
Time frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
Number of Episodes of Each of the Symptoms/Signs Associated to RSV-confirmed ARI Cases
Time frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
Number of Episodes of Each of the Symptoms/Signs Associated to RSV-confirmed LRTD Cases
Time frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
Number of Participants With RSV-confirmed ARI and LRTD Episodes by Severity
The severity was measured as mild, moderate or severe. Mild= An ARI/LRTD episode which is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities. Moderate=An ARI/LRTD episode which is sufficiently discomforting to interfere with normal everyday activities. Severe=An ARI/LRTD episode which prevents normal, everyday activities. Such an event would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.
Time frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
Number of Participants With RSV-confirmed ARI and LRTD Episodes by Frailty Status
The frailty status was evaluated as frail, pre-frail, and fit. Frail=Participants with a walking speed \<0.4 meters per second (m/s) or who were not able to perform the test. Pre-frail=Participants with a walking speed between 0.4-0.99 m/s. Fit=Participants with a walking speed ≥1 m/s.
Time frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
Number of Participants Reporting Any Solicited Administration Site Adverse Events
Assessed solicited administration site adverse events were pain, redness (erythema) and swelling at administration site. Any = occurrence of the symptom regardless of intensity grade.
Time frame: Day 1 (baseline) to Day 7
Number of Participants Reporting Any Solicited Systemic Adverse Events
Assessed solicited systemic adverse events were fever (pyrexia), headache, myalgia (muscle pain), arthralgia (joint pain) and fatigue (tiredness). Fever was defined as body temperature greater or equal to (≥) 38 degrees Celsius (ºC). Any = occurrence of the symptom regardless of intensity grade.
Time frame: Day 1 (baseline) to Day 7
Number of Participants Reporting Any Unsolicited Adverse Events (AEs)
An unsolicited AE was an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs included both serious and non-serious AEs. Any = occurrence of the symptom regardless of intensity grade.
Time frame: Day 1 (baseline) to Day 30
Number of Participants Reporting Any Serious Adverse Events (SAEs), Related SAEs and Fatal SAEs
An SAE is defined as any untoward medical occurrence that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes. Any SAE = occurrence of the SAE regardless of the intensity grade or relation to study vaccination. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of relation to study vaccination.
Time frame: Day 1 to end of study (Month 6 for overseas participants; Month 6 or last ARI visit/contact, whichever is later, for study participants in China)
Number of Participants Reporting Any Potential Immune-mediated Disease (pIMDs) and Related pIMDs
pIMDs are a subset of Adverse Events of Specific Interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any pIMDs = occurrence of the pIMDs regardless of the intensity grade or relation to study vaccination. Related pIMDs = pIMDs assessed by the investigator as related to the study vaccination.
Time frame: Day 1 to end of study (Month 6 for overseas participants; Month 6 or last ARI visit/contact, whichever is later, for study participants in China)
| Milestone | RSV OA Vaccine Group (Overseas) | RSV OA Vaccine Group (China) | Placebo Group (China) |
|---|---|---|---|
| Started | 820 | 1199 | 601 |
| Completed | 812 | 1176 | 589 |
| Not completed | 8 | 23 | 12 |
| Withdrew: Adverse event | 0 | 1 | 1 |
| Withdrew: Death | 2 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 6 | 17 | 10 |
| Withdrew: Other | 0 | 1 | 1 |
RSV-A neutralizing titers were determined by neutralization assay and the results were expressed as GMTs. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.
| Titer | RSV OA Vaccine Group (China) | RSV OA Vaccine Group (Overseas) |
|---|---|---|
| RSV-A Neutralizing Titers Expressed as Adjusted Geometric Mean Titers (GMTs) at 1 Month Post RSVPreF3 OA Vaccination | 5676.7 (5419.3 to 5946.2) | 6329.5 (5973.7 to 6706.5) |
Seroresponse was defined as at least a 4 fold (≥4) increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration).
| Percentage of participants | RSV OA Vaccine Group (China) | RSV OA Vaccine Group (Overseas) |
|---|---|---|
| Percentage of Participants With Seroresponse for RSV-A Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination | 77.3 (74.8 to 79.6) | 76.9 (73.7 to 79.8) |
RSV-B neutralizing titers were determined by neutralization assay and the results were expressed as GMTs. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.
| Titer | RSV OA Vaccine Group (China) | RSV OA Vaccine Group (Overseas) |
|---|---|---|
| RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA Vaccination | 8072.8 (7710.8 to 8451.9) | 8286.8 (7826.4 to 8774.3) |
| Percentage of participants | RSV OA Vaccine Group (China) | RSV OA Vaccine Group (Overseas) |
|---|---|---|
| Percentage of Participants With Seroresponse for RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination | 69.5 (66.8 to 72.2) | 70.3 (66.9 to 73.5) |
Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. Unadjusted GMT is a descriptive statistic calculated directly from the observed titer values at pre-vaccination and at 1-month post-vaccination timepoints for all participants in the analysis set, without any statistical modelling or adjustment for covariates.
| Titer | RSV OA Vaccine Group (China) | RSV OA Vaccine Group (Overseas) |
|---|---|---|
| Day 1 (Baseline) | 703.3 (674.0 to 733.9) | 825.8 (776.6 to 878.1) |
| Day 31 | 5523.2 (5254.7 to 5805.5) | 6604.5 (6194.4 to 7041.7) |
| Day 181 | 2283.4 (2173.7 to 2398.6) | 2395.6 (2253.9 to 2546.3) |
Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. Unadjusted GMT is a descriptive statistic calculated directly from the observed titer values at pre-vaccination and at 1-month post-vaccination timepoints for all participants in the analysis set, without any statistical modelling or adjustment for covariates.
| Titer | RSV OA Vaccine Group (China) | RSV OA Vaccine Group (Overseas) |
|---|---|---|
| Day 1 (Baseline) | 1264.9 (1209.8 to 1322.6) | 1274.2 (1194.6 to 1359.0) |
| Day 31 | 8073.2 (7680.5 to 8485.9) | 8286.2 (7766.3 to 8840.9) |
| Day 181 | 3931.5 (3742.4 to 4130.1) | 3785.0 (3557.0 to 4027.6) |
| Percentage of participants | RSV OA Vaccine Group (China) | RSV OA Vaccine Group (Overseas) |
|---|---|---|
| RSV-A, Day 31 | 77.3 (74.8 to 79.6) | 76.9 (73.7 to 79.8) |
| RSV-A, Day 181 | 36.7 (33.9 to 39.6) | 34.0 (30.7 to 37.4) |
| RSV-B, Day 31 | 69.5 (66.8 to 72.2) | 70.3 (66.9 to 73.5) |
| RSV-B, Day 181 | 36.7 (33.9 to 39.6) | 33.5 (30.2 to 36.9) |
This outcome measure compares the adjusted GMTs for RSV-A and RSV-B for the RSV OA vaccine Group (China) to the selected immunogenicity subset of the global efficacy study RSV OA=ADJ-006 \[RSV OA Overseas (RSV OA=ADJ-006 study) group\]. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.
| Titer | RSV OA Vaccine Group (China) | RSV OA Overseas (RSV OA=ADJ-006 Study) |
|---|---|---|
| RSV-A | 5790.3 (5505.8 to 6089.4) | 8670.5 (8165.7 to 9206.6) |
| RSV-B | 7975.1 (7611.5 to 8356.0) | 10281.3 (9726.6 to 10867.6) |
This outcome measure compares the seroresponse for RSV-A and RSV-B neutralizing titers in the RSV OA vaccine Group (China) group to the selected immunogenicity subset of the global efficacy study RSV OA=ADJ-006 \[RSV OA Overseas (RSV OA=ADJ-006 study) group\].
| Percentage of participants | RSV OA Vaccine Group (China) | RSV OA Overseas (RSV OA=ADJ-006 Study) |
|---|---|---|
| RSV-A | 77.3 (74.8 to 79.6) | 81.6 (78.8 to 84.2) |
| RSV-B | 69.5 (66.8 to 72.2) | 78.6 (75.7 to 81.3) |
ARI and LRTD were reported based on the case definition. Case definition for ARI: presence of at least 2 respiratory symptoms/signs for at least 24 hours or at least 1 respiratory symptom/sign and 1 systemic symptom/sign for at least 24 hours. Case definition for LRTD: presence of at least 2 lower respiratory symptoms/signs for at least 24 hours including at least 1 lower respiratory sign or at least 3 lower respiratory symptoms for at least 24 hours.
| Participants | RSV OA Vaccine Group (China) | Placebo Group (China) |
|---|---|---|
| Any ARI | 163 | 65 |
| RSV-confirmed ARI | 0 | 2 |
| Any LRTD | 29 | 13 |
| RSV-confirmed LRTD | 0 | 1 |
| Days | Placebo Group (China) |
|---|---|
| Duration of RSV-confirmed ARI | 18.5 (17.0 to 20.0) |
| Duration of RSV-confirmed LRTD | 17.0 (17.0 to 17.0) |
| Episodes | Placebo Group (China) |
|---|---|
| Nasal Congestion | 2 |
| Rhinorrhea | 2 |
| Sore Throat | 2 |
| Cough (new or increased) | 2 |
| Sputum (new or increased) | 2 |
| Shortness of breath or dyspnea (new or increased) | 1 |
| Wheezing (new or increased) | 0 |
| Crackles | 0 |
| Rhonchi | 0 |
| Respiratory rate >=20 breaths/min | 0 |
| Low or decreased oxygen saturation | 0 |
| Fever | 1 |
| Feverishness | 0 |
| Fatigue | 2 |
| Body aches | 0 |
| Headache | 0 |
| Decreased appetite | 1 |
| Need for oxygen supplementation | 0 |
| Need for positive airway pressure therapy | 0 |
| Need of other types of mechanical ventilation | 0 |
| Other symptoms or signs | 0 |
| Episodes | Placebo Group (China) |
|---|---|
| Nasal Congestion | 1 |
| Rhinorrhea | 1 |
| Sore Throat | 1 |
| Cough (new or increased) | 1 |
| Sputum (new or increased) | 1 |
| Shortness of breath or dyspnea (new or increased) | 1 |
| Wheezing (new or increased) | 0 |
| Crackles | 0 |
| Rhonchi | 0 |
| Respiratory rate >=20 breaths/min | 0 |
| Low or decreased oxygen saturation | 0 |
| Fever | 1 |
| Feverishness | 0 |
| Fatigue | 1 |
| Body aches | 0 |
| Headache | 0 |
| Decreased appetite | 1 |
| Need for oxygen supplementation | 0 |
| Need for positive airway pressure therapy | 0 |
| Need of other types of mechanical ventilation | 0 |
| Other symptoms or signs | 0 |
The severity was measured as mild, moderate or severe. Mild= An ARI/LRTD episode which is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities. Moderate=An ARI/LRTD episode which is sufficiently discomforting to interfere with normal everyday activities. Severe=An ARI/LRTD episode which prevents normal, everyday activities. Such an event would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.
| Participants | Placebo Group (China) |
|---|---|
| RSV-confirmed ARI — Mild | 1 |
| RSV-confirmed ARI — Moderate | 1 |
| RSV-confirmed ARI — Severe | 0 |
| RSV-confirmed LRTD — Mild | 1 |
| RSV-confirmed LRTD — Moderate | 0 |
| RSV-confirmed LRTD — Severe | 0 |
The frailty status was evaluated as frail, pre-frail, and fit. Frail=Participants with a walking speed \<0.4 meters per second (m/s) or who were not able to perform the test. Pre-frail=Participants with a walking speed between 0.4-0.99 m/s. Fit=Participants with a walking speed ≥1 m/s.
| Participants | Placebo Group (China) |
|---|---|
| RSV-confirmed ARI — Frail | 0 |
| RSV-confirmed ARI — Pre-Frail | 0 |
| RSV-confirmed ARI — Fit | 2 |
| RSV-confirmed LRTD — Frail | 0 |
| RSV-confirmed LRTD — Pre-Frail | 0 |
| RSV-confirmed LRTD — Fit | 1 |
Assessed solicited administration site adverse events were pain, redness (erythema) and swelling at administration site. Any = occurrence of the symptom regardless of intensity grade.
| Participants | RSV OA Vaccine Group (China) | Placebo Group (China) |
|---|---|---|
| Pain | 497 | 25 |
| Erythema | 88 | 3 |
| Swelling | 82 | 0 |
Assessed solicited systemic adverse events were fever (pyrexia), headache, myalgia (muscle pain), arthralgia (joint pain) and fatigue (tiredness). Fever was defined as body temperature greater or equal to (≥) 38 degrees Celsius (ºC). Any = occurrence of the symptom regardless of intensity grade.
| Participants | RSV OA Vaccine Group (China) | Placebo Group (China) |
|---|---|---|
| Arthralgia | 67 | 11 |
| Fatigue | 162 | 19 |
| Headache | 93 | 14 |
| Myalgia | 123 | 12 |
| Fever | 30 | 3 |
An unsolicited AE was an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs included both serious and non-serious AEs. Any = occurrence of the symptom regardless of intensity grade.
| Participants | RSV OA Vaccine Group (China) | Placebo Group (China) |
|---|---|---|
| Number of Participants Reporting Any Unsolicited Adverse Events (AEs) | 165 | 70 |
An SAE is defined as any untoward medical occurrence that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes. Any SAE = occurrence of the SAE regardless of the intensity grade or relation to study vaccination. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of relation to study vaccination.
| Participants | RSV OA Vaccine Group (Overseas) | RSV OA Vaccine Group (China) | Placebo Group (China) |
|---|---|---|---|
| Any SAEs | 28 | 53 | 39 |
| Related SAEs | 0 | 2 | 2 |
| Fatal SAEs | 2 | 2 | 0 |
pIMDs are a subset of Adverse Events of Specific Interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any pIMDs = occurrence of the pIMDs regardless of the intensity grade or relation to study vaccination. Related pIMDs = pIMDs assessed by the investigator as related to the study vaccination.
| Participants | RSV OA Vaccine Group (Overseas) | RSV OA Vaccine Group (China) | Placebo Group (China) |
|---|---|---|---|
| Any pIMDs | 2 | 3 | 1 |
| Related pIMDs | 0 | 0 | 1 |
Collected over Solicited AEs: Day 1 (day of vaccination) up to Day 7. Unsolicited AEs: Day 1 up to Day 30. All-cause mortality, any SAEs, related SAEs, fatal SAEs, any pIMDs, related pIMDs: Day 1 up to study end (Month 6 for oversea participants; Month 6 or or last ARI visit/contact, whichever is later, for participants in China). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RSV OA Vaccine Group (Overseas) | 2/820 (0.2%) | 28/820 (3.4%) | 2/820 (0.2%) |
| RSV OA Vaccine Group (China) | 2/1,199 (0.2%) | 53/1,199 (4.4%) | 640/1,199 (53.4%) |
| Placebo Group (China) | 0/601 (0%) | 39/601 (6.5%) | 108/601 (18%) |
| Event | RSV OA Vaccine Group (Overseas) | RSV OA Vaccine Group (China) | Placebo Group (China) |
|---|---|---|---|
| PneumoniaInfections and infestations | 2/820 | 3/1199 | 4/601 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/820 | 6/1199 | 1/601 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/820 | 5/1199 | 3/601 |
| Deep vein thrombosisVascular disorders | 3/820 | 0/1199 | 0/601 |
| Inguinal herniaGastrointestinal disorders | 0/820 | 0/1199 | 2/601 |
| Cerebral infarctionNervous system disorders | 0/820 | 3/1199 | 2/601 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/820 | 1/1199 | 2/601 |
| HypertensionVascular disorders | 0/820 | 2/1199 | 2/601 |
| ConcussionInjury, poisoning and procedural complications | 2/820 | 0/1199 | 0/601 |
| Acute myocardial infarctionCardiac disorders | 0/820 | 2/1199 | 1/601 |
| Event | RSV OA Vaccine Group (Overseas) | RSV OA Vaccine Group (China) | Placebo Group (China) |
|---|---|---|---|
| Injection site painGeneral disorders | 0/820 | 497/1199 | 25/601 |
| FatigueGeneral disorders | 0/820 | 164/1199 | 19/601 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/820 | 125/1199 | 12/601 |
| HeadacheNervous system disorders | 0/820 | 95/1199 | 15/601 |
| Injection site erythemaGeneral disorders | 0/820 | 88/1199 | 3/601 |
| Injection site swellingGeneral disorders | 0/820 | 82/1199 | 0/601 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/820 | 69/1199 | 11/601 |
| PyrexiaGeneral disorders | 0/820 | 49/1199 | 8/601 |
| Upper respiratory tract infectionInfections and infestations | 0/820 | 19/1199 | 11/601 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/820 | 12/1199 | 2/601 |
| Age, Continuous(YEARS) | RSV OA Vaccine Group (Overseas) | RSV OA Vaccine Group (China) | Placebo Group (China) | Total |
|---|---|---|---|---|
| Mean | 70.5 ± 6.8 | 69.8 ± 6.6 | 69.9 ± 6.7 | 70.1 ± 6.7 |
| Sex: Female, Male(Participants) | RSV OA Vaccine Group (Overseas) | RSV OA Vaccine Group (China) | Placebo Group (China) | Total |
|---|---|---|---|---|
| Female | 439 | 618 | 304 | 1361 |
| Male | 381 | 581 | 297 | 1259 |
| Race/Ethnicity, Customized(Participants) | RSV OA Vaccine Group (Overseas) | RSV OA Vaccine Group (China) | Placebo Group (China) | Total |
|---|---|---|---|---|
| Asian | 106 | 1199 | 601 | 1906 |
| White | 707 | 0 | 0 | 707 |
| American Indian or Alaskan Native | 3 | 0 | 0 | 3 |
| Black or African American | 4 | 0 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Aug 2024 to primary completion in Apr 2025, 8 months.
Results were first posted in May 2026, 1 year after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 8 months is close to that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arexvy
Respiratory Syncytial Virus Infections →